The Fund's objective is to achieve long term capital and income growth.
Name | % Net Assets |
---|---|
AstraZeneca PLC | 1.9% |
Royal Dutch Shell PLC (CL B) | 1.8% |
GlaxoSmithKline PLC | 1.8% |
Centrica PLC | 1.6% |
Daily Mail & General Trust PLC | 1.5% |
RSA Insurance Group PLC | 1.5% |
British American Tobacco PLC | 1.5% |
VT Group PLC | 1.5% |
Babcock International Group PLC | 1.4% |
Smith & Nephew PLC | 1.3% |
Key | % Net Assets |
---|---|
AstraZeneca PLC | 1.9% |
Royal Dutch Shell PLC (CL B) | 1.8% |
GlaxoSmithKline PLC | 1.8% |
Centrica PLC | 1.6% |
Other | 92.9% |
Date | 21-Nov-2024 |
---|---|
NAV | 324.30p |
Currency | GBP |
Change | -2.00p |
% | -0.61% |
YTD change | -1.40p |
YTD % | -0.43% |
Fund Inception | 31/12/2002 |
---|---|
Fund Manager | Tim Russell |
TER | 1.58 (30-Apr-2011) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | £500 |
Savings | n/a |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.10 |
You are here: research